# STOPP/START v3 Criteria (Full List)

Source: Appendix 1 from the STOPP/START v3 publication (CC BY 4.0).

## STOPP v3 (Potentially Inappropriate Medications)

The following prescriptions are potentially inappropriate to use in patients aged 65 years and older.

### Section A: Indication of Medication
1. Any drug prescribed without a clinical indication.
2. Any drug prescribed beyond the recommended duration, where treatment duration is well defined.
3. Any duplicate drug class prescription for daily regular use (as distinct from PRN use), e.g., two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants, antipsychotics, opioid analgesics (optimisation of monotherapy within a single drug class should be observed prior to considering a new agent).

### Section B: Cardiovascular System
1. Digoxin for heart failure with normal systolic ventricular function (no clear evidence of benefit).
2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure with reduced ejection fraction).
3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block).
4. Ventricular rate-limiting drugs (beta blocker, verapamil, diltiazem, digoxin) with bradycardia (<50/min), type II heart block or complete heart block (risk of complete heart block, asystole).
5. Beta-blocker as monotherapy for uncomplicated hypertension not associated with angina pectoris, aortic aneurysm or other condition where beta-blocker therapy is indicated (no firm evidence of efficacy).
6. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of major side-effects than beta-blockers, digoxin, verapamil or diltiazem).
7. Loop diuretic as first-line treatment for hypertension unless there is concurrent heart failure requiring diuretic therapy (safer, more effective alternatives available).
8. Loop diuretic for dependent ankle oedema without clinical, biochemical or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and/or compression hosiery usually more appropriate).
9. Thiazide diuretic with current significant hypokalaemia (serum K+ <3.0 mmol/L), hyponatraemia (serum Na+ <130 mmol/L), hypercalcaemia (corrected serum calcium >2.65 mmol/L) or with a history of gout.
10. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may exacerbate incontinence).
11. Centrally acting antihypertensives (e.g., methyldopa, clonidine, moxonidine, rilmenidine, guanfacine) (less well tolerated by older people).
12. ACE inhibitors or ARBs in patients with hyperkalaemia (serum K >5.5 mmol/L).
13. Aldosterone antagonists (spironolactone, eplerenone) with concurrent potassium-conserving drugs (ACEIs, ARBs, amiloride, triamterene) without monitoring serum potassium (risk of dangerous hyperkalaemia >6.0 mmol/L).
14. PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) in severe heart failure characterised by hypotension (SBP <90 mmHg) or concurrent nitrate therapy (risk of cardiovascular collapse).
15. Drugs that predictably prolong QTc in patients with known QTc prolongation (>450 msec in males, >470 msec in females), including quinolones, macrolides, ondansetron, citalopram >20 mg/day, escitalopram >10 mg/day, tricyclic antidepressants, lithium, haloperidol, digoxin, class 1A antiarrhythmics, class III antiarrhythmics, tizanidine, phenothiazines, astemizole, mirabegron (risk of life-threatening ventricular arrhythmias).
16. Statins for primary cardiovascular prevention in persons aged >=85 with established frailty and life expectancy likely <3 years (lack of evidence of efficacy).
17. Long-term systemic (non-topical) NSAIDs with known history of coronary, cerebral or peripheral vascular disease (increased risk of thrombosis).
18. Long-term antipsychotics with known history of coronary, cerebral or peripheral vascular disease (increased risk of thrombosis).
19. NSAIDs or systemic corticosteroids with heart failure requiring loop diuretic therapy (risk of exacerbation of heart failure).
20. Antihypertensive drugs in severe symptomatic aortic stenosis (risk of severe hypotension, syncope).
21. Digoxin as first-line treatment for long-term (>3 months) ventricular rate control in atrial fibrillation (increased mortality from long-term digoxin use; cardio-selective beta-blockers generally preferable).

### Section C: Coagulation System
1. Long-term aspirin at doses >100 mg/day (increased risk of bleeding, no evidence for increased efficacy).
2. Antiplatelet agents, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors with concurrent significant risk of major bleeding (uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding).
3. Aspirin plus clopidogrel as long-term secondary stroke prevention (>4 weeks), unless coronary stent in previous 12 months, concurrent acute coronary syndrome, or high-grade symptomatic carotid stenosis.
4. Antiplatelet agents with VKA/direct thrombin/factor Xa inhibitors in chronic AF unless concurrent coronary stent(s) or angiographically proven high-grade (>50%) coronary artery stenosis.
5. Antiplatelet agents with VKA/direct thrombin/factor Xa inhibitors in stable coronary, cerebrovascular or peripheral arterial disease.
6. Ticlopidine in any circumstances.
7. Antiplatelet agents as alternatives to VKA/direct thrombin/factor Xa inhibitors for stroke prevention in chronic AF.
8. VKA/direct thrombin/factor Xa inhibitors for first DVT without continuing provoking risk factors for longer than 6 months.
9. VKA/direct thrombin/factor Xa inhibitors for first pulmonary embolus without continuing provoking risk factors for longer than 12 months.
10. NSAIDs with VKA/direct thrombin/factor Xa inhibitors in combination (risk of major GI bleeding).
11. VKA as first-line anticoagulant for AF unless metallic heart valve, moderate-to-severe mitral stenosis, or eGFR <15 ml/min/1.73m2.
12. SSRIs with VKA/direct thrombin/factor Xa inhibitor in a patient with previous major haemorrhage.
13. Direct thrombin inhibitor (dabigatran) with diltiazem or verapamil (increased bleeding risk).
14. Apixaban, dabigatran, edoxaban, rivaroxaban with P-gp inhibitors (amiodarone, azithromycin, carvedilol, cyclosporin, dronedarone, itraconazole, ketoconazole systemic, macrolides, quinine, ranolazine, tamoxifen, ticagrelor, verapamil) (increased bleeding risk).
15. Systemic oestrogens or androgens with previous history of venous thromboembolism (increased risk of recurrence).
16. Aspirin for primary prevention in cardiovascular disease (no evidence of benefit).

### Section D: Central Nervous System
1. Tricyclic antidepressants (TCAs) in dementia, narrow-angle glaucoma, cardiac conduction abnormalities, prostatism, chronic constipation, recent falls, prior urinary retention, or orthostatic hypotension (risk of worsening these conditions).
2. Initiation of TCAs as first-line treatment for major depression (higher risk of adverse drug reactions than SSRIs/SNRIs).
3. SNRIs (e.g., venlafaxine, duloxetine) with severe hypertension (SBP >180 mmHg +/- DBP >105 mmHg).
4. Antipsychotics with moderate-marked antimuscarinic effects (acepromazine, chlorpromazine, clozapine, flupenthixol, fluphenzine, levomepromazine, olanzapine, pipothiazine, promazine, thioridazine) with lower urinary tract symptoms or prior urinary retention.
5. Antipsychotics for BPSD at an unchanged dose >3 months without medication review (increased extrapyramidal effects and chronic cognitive worsening, increased CV morbidity/mortality).
6. SSRIs with current or recent significant hyponatraemia (serum Na+ <130 mmol/L).
7. SSRIs with current or recent significant bleeding (risk of recurrence from antiplatelet effects).
8. Benzodiazepines for >=4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls; withdraw gradually if >4 weeks).
9. Benzodiazepines for agitated behaviour or psychotic symptoms of dementia (no evidence of efficacy).
10. Benzodiazepines for insomnia for >=2 weeks (high dependency risk, falls, fractures, RTAs).
11. Z-drugs (zolpidem, zopiclone, zaleplon) for insomnia for >=2 weeks (risk of falls/fractures).
12. Antipsychotics (other than clozapine or quetiapine) in parkinsonism or Dementia with Lewy Bodies (risk of severe extrapyramidal symptoms).
13. Anticholinergic/antimuscarinic drugs (biperiden, orphenadrine, procyclidine, trihexyphenidyl) to treat extrapyramidal side-effects of antipsychotics (risk of anticholinergic toxicity).
14. Drugs with potent anticholinergic/antimuscarinic effects in patients with delirium or dementia (risk of exacerbating cognitive impairment).
15. Antipsychotics in BPSD for >12 weeks unless symptoms are severe and non-pharmacologic treatments failed (increased risk of stroke/MI).
16. Antipsychotics as hypnotics unless sleep disorder is due to psychosis or BPSD (risk of confusion, hypotension, extrapyramidal effects, falls).
17. Acetylcholinesterase inhibitors with persistent bradycardia (<60 bpm), heart block, or recurrent unexplained syncope (risk of conduction failure/syncope).
18. Acetylcholinesterase inhibitors with concurrent drugs that induce bradycardia (beta-blockers, digoxin, diltiazem, verapamil).
19. Memantine with known current or previous seizure disorder (increased seizure risk).
20. Nootropics in dementia (Ginkgo biloba, piracetam, pramiracetam, phenylpiracetam, aniracetam, phosphatidylserine, modafinil, L-theanine, omega-3 fatty acids, panax ginseng, rhodiola, creatine) (no evidence of efficacy).
21. Phenothiazines as first-line treatment for psychosis or non-cognitive symptoms of dementia (safer alternatives exist; phenothiazines have significant antimuscarinic toxicity, except for prochlorperazine for nausea/vertigo, chlorpromazine for persistent hiccoughs, levomepromazine as anti-emetic in palliative care).
22. Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy).
23. Levodopa or dopamine agonists for treatment of extrapyramidal side-effects of antipsychotics or other drug-induced Parkinsonism (inappropriate prescribing cascade).
24. First-generation antihistamines as first-line treatment for allergy or pruritus (safer alternatives available).
25. First-generation antihistamines for insomnia (high risk of side-effects; Z-drugs safer for short-term use).

### Section E: Renal System
The following commonly prescribed drugs are potentially inappropriate in older people with acute or chronic kidney disease with impaired renal function below particular levels of eGFR.

1. Digoxin at long-term maintenance dose >=125 microg/day if eGFR <30 ml/min/1.73m2 (risk of digoxin toxicity if plasma levels not measured).
2. Direct thrombin inhibitors (e.g., dabigatran) if eGFR <30 ml/min/1.73m2 (risk of bleeding).
3. Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban) if eGFR <15 ml/min/1.73m2 (risk of bleeding).
4. NSAIDs if eGFR <50 ml/min/1.73m2 (risk of deterioration in renal function).
5. Colchicine if eGFR <10 ml/min/1.73m2 (risk of colchicine toxicity).
6. Metformin if eGFR <30 ml/min/1.73m2 (risk of lactic acidosis).
7. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) if eGFR <30 ml/min/1.73m2 (risk of dangerous hyperkalaemia).
8. Nitrofurantoin if eGFR <45 ml/min/1.73m2 (increased risk of nitrofurantoin toxicity).
9. Bisphosphonates if eGFR <30 ml/min/1.73m2 (increased risk of acute renal failure).
10. Methotrexate if eGFR <30 ml/min/1.73m2 (increased risk of methotrexate toxicity).

### Section F: Gastrointestinal System
1. Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian symptoms).
2. Proton pump inhibitor (PPI) for uncomplicated peptic ulcer disease at full therapeutic dosage >8 weeks (dose reduction or earlier discontinuation or H2 antagonist maintenance therapy usually indicated).
3. Drugs likely to cause constipation (systemic antimuscarinics, oral iron, opioids, verapamil, aluminium antacids) with chronic constipation where non-constipating alternatives are available.
4. Oral elemental iron doses >200 mg daily (e.g., ferrous fumarate >600 mg/day, ferrous sulphate >600 mg/day, ferrous gluconate >1800 mg/day; no evidence of enhanced absorption above these doses).
5. Corticosteroids with a history of peptic ulcer disease or erosive oesophagitis (risk of relapse unless PPI co-prescribed).
6. Antiplatelet or anticoagulant drugs with history of Gastric Antral Vascular Ectasia (GAVE) (risk of major GI bleeding).
7. Antipsychotics with dysphagia (increased risk of aspiration pneumonia).
8. Megestrol acetate to increase appetite (increased risk of thrombosis and death with unproven efficacy).

### Section G: Respiratory System
1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk due to narrow therapeutic index).
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to systemic side-effects; effective inhaled therapies available).
3. Long-acting muscarinic antagonists (tiotropium, aclidinium, umeclidinium, glycopyrronium) with a history of narrow-angle glaucoma or bladder outflow obstruction (may exacerbate glaucoma or cause urinary retention).
4. Benzodiazepines with acute or chronic respiratory failure (pO2 <8.0 kPa +/- pCO2 >6.5 kPa) (risk of respiratory failure exacerbation).

### Section H: Musculoskeletal System
1. NSAIDs other than COX-2 selective agents with history of peptic ulcer disease or GI bleeding unless concurrent PPI or H2 antagonist.
2. NSAIDs with severe hypertension (SBP consistently >170 mmHg and/or DBP consistently >100 mmHg).
3. Long-term NSAID use (>3 months) for osteoarthritis pain where paracetamol has not been tried.
4. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis (systemic side-effects).
5. Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for osteoarthritis (systemic side-effects).
6. Long-term NSAID or colchicine (>3 months) for chronic gout where no contraindication to xanthine-oxidase inhibitor (e.g., allopurinol, febuxostat).
7. NSAID with concurrent corticosteroids for treatment of arthritis/rheumatism (increased risk of peptic ulcer disease).
8. Oral bisphosphonates with current or recent upper GI disease (dysphagia, oesophagitis, gastritis, duodenitis, peptic ulcer disease, or upper GI bleed) (risk of relapse/exacerbation).
9. Long-term opioids for osteoarthritis (lack of evidence of efficacy; increased serious side-effects).

### Section I: Urogenital System
1. Systemic antimuscarinic drugs (oxybutynin, tolterodine, trospium) with dementia or chronic cognitive impairment (risk of confusion/agitation).
2. Systemic antimuscarinic drugs (oxybutynin, tolterodine, trospium) with narrow-angle glaucoma (risk of acute exacerbation).
3. Systemic antimuscarinic drugs for LUTS with BPH and high post-void residual volume (>200 ml) (risk of urinary retention).
4. Systemic antimuscarinic drugs with constipation (risk of exacerbation).
5. Alpha-1 receptor antagonists other than silodosin (alfuzosin, doxazosin, indoramin, tamsulosin, terazosin) with symptomatic orthostatic hypotension or history of syncope.
6. Mirabegron in labile or severe hypertension (risk of exacerbation).
7. Duloxetine with urinary urgency or urge incontinence (not indicated for urgency/urge incontinence).
8. Antibiotic use in asymptomatic bacteriuria (no indication for treatment).

### Section J: Endocrine System
1. Sulphonylureas with long half-life (glibenclamide, chlorpropamide, glimepiride) with type 2 diabetes (risk of prolonged hypoglycaemia).
2. Thiazolidinediones (rosiglitazone, pioglitazone) with heart failure (risk of exacerbation).
3. Non-selective beta-blockers in diabetes with frequent hypoglycaemic episodes (risk of suppressing symptoms).
4. SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) with symptomatic hypotension (risk of exacerbation).
5. Systemic oestrogens with history of breast cancer (risk of recurrence).
6. Systemic oestrogens with history of venous thromboembolism (risk of recurrence).
7. Menopausal hormone therapy (oestrogen + progestin) with history of stenotic coronary, cerebral or peripheral arterial disease (risk of arterial thrombosis).
8. Systemic oestrogens without progestogens in patients with intact uterus (risk of endometrial cancer).
9. Levothyroxine in subclinical hypothyroidism (normal free T4, elevated TSH <10 mU/L) (no evidence of benefit; risk of iatrogenic thyrotoxicosis).
10. Vasopressin analogues (desmopressin, vasopressin) for urinary incontinence or urinary frequency (risk of hyponatraemia).

### Section K: Drug Classes That Predictably Increase Falls Risk in Susceptible Older People
1. Benzodiazepines in patients with recurrent falls (may reduce sensorium, impair balance).
2. Antipsychotic drugs in patients with recurrent falls (may cause Parkinsonism).
3. Vasodilator drugs in patients with recurrent falls with persistent postural hypotension (SBP drop >=20 mmHg and/or DBP drop >=10 mmHg).
4. Hypnotic Z-drugs (zopiclone, zolpidem, zaleplon) in patients with recurrent falls (daytime sedation, ataxia).
5. Anti-epileptic drugs in patients with recurrent falls (may impair sensorium, affect cerebellar function).
6. First-generation antihistamines in patients with recurrent falls (may impair sensorium).
7. Opioids in patients with recurrent falls (may impair sensorium).
8. Antidepressants in patients with recurrent falls (may impair sensorium).
9. Alpha blockers as antihypertensives in patients with recurrent falls (may cause orthostatic hypotension).
10. Alpha blockers for prostatic bladder outflow symptoms other than silodosin in patients with recurrent falls (may cause orthostatic hypotension).
11. Centrally acting antihypertensives (may impair sensorium and cause orthostatic hypotension).
12. Antimuscarinics for overactive bladder or urge incontinence (may impair sensorium).

### Section L: Analgesic Drugs
1. Oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, methadone, tramadol, pethidine, pentazocine) as first-line therapy for mild pain (WHO analgesic ladder not observed).
2. Daily regular opioids without concomitant laxative (risk of severe constipation).
3. Long-acting opioids without short-acting opioids for break-through moderate/severe pain (risk of persistent severe pain).
4. Topical lidocaine (lignocaine) patch for chronic osteoarthritis pain (lack of evidence of efficacy).
5. Gabapentinoids (gabapentin, pregabalin) for non-neuropathic pain (lack of evidence of efficacy).
6. Paracetamol at doses >=3 g/24 hours in patients with poor nutritional status (BMI <18) or chronic liver disease (risk of hepatotoxicity).

### Section M: Antimuscarinic/Anticholinergic Drug Burden
1. Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (bladder antispasmodics, intestinal antispasmodics, TCAs, first-generation antihistamines, antipsychotics) (risk of increased toxicity).

## START v3 (Potential Prescribing Omissions)

Unless an elderly patient’s clinical status is end-of-life and therefore requiring a more palliative focus of pharmacotherapy, the following drug therapies should be considered where omitted for no valid clinical reason(s). It is assumed that the prescriber observes all specific contraindications prior to recommending these therapies.

### Section A: Indicated Drugs
1. Where a drug is clearly indicated and appropriate in the particular clinical context, and there is no clear contraindication, that drug should be initiated as per formulary guidelines for dose and duration.

### Section B: Cardiovascular System
1. Antihypertensive therapy where SBP >140 mmHg and/or DBP >90 mmHg, unless established moderate/severe physical frailty where threshold is SBP 150 mmHg and/or DBP 90 mmHg.
2. Statin therapy with documented coronary, cerebral or peripheral vascular disease, unless end-of-life or established moderate/severe frailty.
3. ACE inhibitor with coronary artery disease.
4. Beta-blocker with symptomatic coronary artery disease.
5. ACE inhibitor for heart failure with reduced ejection fraction.
6. Cardio-selective beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) for stable HFrEF.
7. Mineralocorticoid receptor antagonist (spironolactone, eplerenone) in heart failure without severe renal impairment (eGFR >30 ml/min/m2).
8. SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) in symptomatic heart failure with or without reduced EF regardless of diabetes.
9. Sacubitril/valsartan in HFrEF with persistent symptoms despite optimal ACEI/ARB (replace ACEI/ARB).
10. Beta-blocker for chronic AF with uncontrolled heart rate.
11. Intravenous iron for symptomatic HFrEF with iron deficiency.

### Section C: Coagulation System
1. Vitamin K antagonist or direct thrombin inhibitor or factor Xa inhibitor in chronic or paroxysmal AF.
2. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with documented coronary, cerebral or peripheral vascular disease.

### Section D: Central Nervous System
1. L-DOPA or dopamine agonist in idiopathic Parkinson’s disease with functional impairment.
2. Non-TCA antidepressant for major depression.
3. Acetylcholinesterase inhibitor (donepezil, rivastigmine, galantamine) for mild-moderate Alzheimer’s dementia.
4. Rivastigmine for Dementia with Lewy Bodies or Parkinson’s disease dementia.
5. SSRI (or SNRI or pregabalin if SSRI contraindicated) for persistent severe anxiety affecting independent function/QoL.
6. Dopamine agonist (ropinirole, pramipexole, rotigotine) for Restless Legs Syndrome after excluding iron deficiency and severe CKD (eGFR <30 ml/min/m2).
7. Propranolol for essential tremor with functional impairment.

### Section E: Renal System
1. One-alpha hydroxycholecalciferol or calcitriol in severe CKD (eGFR <30 ml/min/m2) with hypocalcaemia (corrected calcium <2.10 mmol/L) and secondary hyperparathyroidism.
2. Phosphate binder in severe CKD (eGFR <30 ml/min/m2) if serum phosphate persistently >1.76 mmol/L (5.5 mg/dL) despite renal diet.
3. Erythropoietin analogue in severe CKD (eGFR <30 ml/min/m2) with symptomatic anaemia not due to haematinic/iron deficiency to achieve hemoglobin 10.0 to 12.0 g/dL.
4. ARB or ACE-I in CKD with proteinuria (urine albumin excretion >300 mg/24 hours).

### Section F: Gastrointestinal System
1. PPI with severe GERD or peptic oesophageal stricture requiring dilatation.
2. PPI with initiation of low-dose aspirin and previous history of peptic ulcer or reflux oesophagitis.
3. PPI with short-term (<2 weeks) or longer-term (>2 weeks) NSAID.
4. Fibre supplements (bran, ispaghula, methylcellulose, sterculia) for diverticulosis with constipation history.
5. Osmotic laxative (lactulose, macrogol, sorbitol) for chronic persistent idiopathic or secondary benign constipation.
6. Probiotics with antibiotics in patients not immunocompromised or severely debilitated for prevention of C. difficile-associated diarrhea.
7. H. pylori eradication therapy in HP-associated active peptic ulcer disease.

### Section G: Respiratory System
1. LAMA (tiotropium, aclidinium, umeclidinium, glycopyrronium) or LABA (bambuterol, formoterol, indacaterol, olodaterol, salmeterol) for symptomatic COPD GOLD 1-2 and chronic asthma.
2. Regular daily inhaled corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone, mometasone) for moderate-severe asthma or COPD GOLD 3-4 where FEV1 <50% predicted and repeated exacerbations requiring oral corticosteroids.
3. Home continuous oxygen with documented chronic hypoxaemia (pO2 <8.0 kPa or 60 mmHg or SaO2 <89%).

### Section H: Musculoskeletal System
1. DMARD with chronic, active and disabling rheumatoid arthritis.
2. Bisphosphonates + vitamin D + calcium in patients taking long-term systemic corticosteroids for prevention of steroid-induced osteoporosis.
3. Vitamin D in patients with known osteoporosis and/or previous fragility fracture(s) and/or BMD T-scores below -2.5.
4. Bone anti-resorptive or anabolic therapy (bisphosphonate, teriparatide, denosumab) in documented osteoporosis (BMD T-scores below -2.5) and/or previous fragility fracture(s), where no pharmacological/clinical contraindication exists (e.g., poor one-year life expectancy).
5. Vitamin D supplement in older people with confirmed 25-hydroxycolecalciferol deficiency (<20 micrograms/L, <50 nmol/L) who are housebound or experiencing falls or with osteopenia (BMD T-score < -1.0 but above -2.5).
6. Anti-resorptive treatment after discontinuation of at least two doses of denosumab (rebound increased bone turnover, BMD loss, vertebral fracture risk).
7. Anti-resorptive treatment after discontinuation of teriparatide/abaloparatide treatment for osteoporosis.
8. Xanthine-oxidase inhibitors (allopurinol, febuxostat) with history of recurrent gout episodes.
9. Folic acid supplement in patients taking methotrexate.

### Section I: Urogenital System
1. Selective alpha-1 receptor blocker (tamsulosin, silodosin) for LUTS related to BPH where prostatectomy is not considered necessary/appropriate/safe.
2. 5-alpha reductase inhibitor (finasteride, dutasteride) for LUTS related to BPH where prostatectomy is not considered necessary/appropriate/safe.
3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis.
4. Topical vaginal oestrogen or vaginal oestrogen pessary in women for recurrent UTIs.
5. PDE-5 inhibitors (avanafil, sildenafil, tadalafil, vardenafil) for persistent erectile dysfunction that causes distress.

### Section J: Endocrine System
1. ACE inhibitor or ARB (if ACE inhibitor intolerant) in diabetes with evidence of renal disease (dipstick proteinuria or microalbuminuria >30 mg/24 hours) unless severe CKD (eGFR <30 ml/min/m2).

### Section K: Analgesics
1. High-potency opioids in moderate-severe non-arthritis pain where paracetamol, NSAIDs or low-potency opioids are not appropriate to pain severity or have been ineffective.
2. Laxatives in patients receiving opioids regularly (other than PRN use).
3. Topical 5% lidocaine (lignocaine) patch for localized neuropathic pain (e.g., post-herpetic neuralgia).

### Section L: Vaccines
1. Seasonal influenza vaccine annually.
2. Pneumococcal vaccine at least once according to national guidelines.
3. Varicella-zoster vaccine according to national guidelines.
4. SARS-CoV-2 vaccine according to national guidelines.

## References
See: [references/geriatrics-tools-sources.md](../references/geriatrics-tools-sources.md)
